Neurological Disorders Evaluation Flashcards

A commercial driver presents with a confirmed diagnosis of narcolepsy with cataplexy, currently managed with sodium oxybate and modafinil. He reports complete symptom control for 14 months with no EDS episodes. Under FMCSA guidelines, what is the appropriate certification decision?

Answer: Disqualify permanently, as narcolepsy with cataplexy is an absolute disqualifying condition regardless of treatment

FMCSA explicitly lists narcolepsy as a disqualifying condition under 49 CFR 391.41(b)(8). Unlike some neurological conditions where treatment can restore certification eligibility, narcolepsy with cataplexy is permanently disqualifying regardless of how well symptoms are controlled by medication. The underlying disorder's potential for sudden incapacitation makes pharmacological management insufficient for commercial driving clearance.

A 52-year-old CDL holder had a single unprovoked tonic-clonic seizure 9 months ago. He was placed on levetiracetam and has been seizure-free since. His neurologist states that the EEG is now normal and the seizure risk has returned to near-baseline. Under FMCSA standards, what is the earliest he can be considered for recertification?

Answer: After a minimum of 5 years seizure-free, regardless of medication status

FMCSA regulations under 49 CFR 391.41(b)(8) disqualify drivers with epilepsy or any condition likely to cause loss of consciousness. The long-standing FMCSA standard requires 5 years seizure-free before even consideration for a federal exemption through the Epilepsy Exemption Program. Being on medication does not shorten this window — the 5-year seizure-free threshold applies regardless of treatment status.

During evaluation of a 61-year-old interstate truck driver, the ME discovers he had a TIA 4 months ago with full neurological recovery. He is now on dual antiplatelet therapy. CT angiography shows no significant stenosis. His neurologist has cleared him to return to driving. What should the ME do?

Answer: Deny certification until 12 months have passed from the TIA event, regardless of recovery

FMCSA guidance treats TIA as a serious cerebrovascular event with high short-term stroke recurrence risk. While TIAs cause no permanent deficits by definition, the ME must consider whether the underlying vascular condition creates an ongoing risk of sudden incapacitation. The standard approach requires at least 12 months from the event before certification can be considered, even with full recovery and specialist clearance, to allow adequate time to assess recurrence risk and vascular stability.

A CDL applicant discloses a history of multiple sclerosis (MS) diagnosed 6 years ago. He currently has no active lesions on MRI, EDSS score of 1.0, and no relapses in 3 years. His neurologist states he is clinically stable on natalizumab. Which statement best describes the correct NRCME evaluation approach?

Answer: Certify for 2 years if no disqualifying findings are present on the physical examination and functional criteria are met

MS is not categorically disqualifying under FMCSA regulations. The ME must evaluate each driver individually based on current functional status, examining for disqualifying deficits such as limb weakness affecting vehicle control, vision impairment, or cognitive dysfunction. If the driver meets all physical qualification standards and no disqualifying conditions are identified on examination, the standard 2-year certificate is appropriate. The diagnosis alone does not mandate a shortened certification period, though the ME may use clinical judgment.

An ME is evaluating a 47-year-old driver who underwent a resection for a low-grade cerebral glioma (WHO Grade II) 26 months ago. He received no radiation or chemotherapy. He has been seizure-free and has no neurological deficits. His neuro-oncologist provides a letter stating no evidence of recurrence on recent MRI. Which factor is MOST critical in determining certification eligibility?

Answer: Seizure history and whether the driver meets the applicable seizure-free threshold under FMCSA standards

For brain tumor survivors, the FMCSA evaluation centers primarily on whether the driver has had seizures and whether the applicable seizure-free threshold has been met. Grade II gliomas carry inherent epileptogenic potential both from the tumor and from surgical manipulation of brain tissue. Even in the absence of active tumor, the ME must establish a seizure-free period consistent with FMCSA standards before certification. The absence of recurrence is necessary but not sufficient — the seizure history and risk are the controlling factors.

A driver presents with a diagnosis of restless legs syndrome (RLS) causing severe sleep fragmentation. His sleep study shows no concurrent obstructive sleep apnea. He is being treated with ropinirole, but reports that augmentation has developed, causing symptoms to now begin in late afternoon. He denies EDS on the Epworth Sleepiness Scale (score 7) but admits to difficulty initiating sleep. What is the MOST appropriate certification action?

Answer: Disqualify until augmentation is resolved and a sleep specialist confirms sleep quality has been restored

While RLS itself is not a categorically disqualifying condition, the ME must evaluate whether the condition — particularly when complicated by dopaminergic augmentation — results in insufficient restorative sleep that impairs safe driving. Augmentation represents a treatment failure causing worsening and earlier symptom onset, effectively undermining the adequacy of the therapeutic regimen. The driver's sleep fragmentation from afternoon-onset RLS symptoms represents a significant sleep quality concern that must be clinically resolved and documented before commercial vehicle operation can be safely certified. The acceptable ESS score does not override objective evidence of sleep disruption.